To our knowledge, here, we report for the first time that EGFR-TKI resistance through acquired KRAS mutation could be dependent on the exon location or type of mutation of the original EGFR-sensitizing mutation, suggesting that tumor resistance could be driven by the position in the genome of the original EGFR mutation. Here, KRAS is linked to neoplasm.